TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8426717

Group type: EXPERIMENTAL
Intervention: 0.025% fluocinonide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2890522

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 2395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2395
Study: 30503723

Group type: EXPERIMENTAL
Intervention: Accelerated Seldinger technique with combination CVC device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified Seldinger technique with standard CVC kit
Number of subjects: 0
Study: 27819431

Group type: EXPERIMENTAL
Intervention: Alcohol mixed with energy drinks (AmED)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Energy drink conditions
Number of subjects: 16
Study: 24871705

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg Methylnaltrexone (MTNX)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.225 mg/kg Methylnaltrexone (MTNX)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.143 mg/kg Morphine sulfate
Number of subjects: 29
Study: 23341547

Group type: EXPERIMENTAL
Intervention: Stress management intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 45
Study: 20661660

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg Se as Se-rich yeast)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (baker's yeast)
Number of subjects: 42
Study: 19204390

Group type: EXPERIMENTAL
Intervention: 5,000 ppm NaF toothpaste without postbrushing water rinsing
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1,450 ppm NaF toothpaste with water rinsing
Number of subjects: 26

Group type: COMPARATOR
Intervention: 5,000 ppm NaF toothpaste with postbrushing water rinsing
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1,450 ppm NaF toothpaste without water rinsing
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of 5,000 ppm without rinsing and 1,450 ppm with rinsing
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of fluoride concentration per unit weight of plaque
Number of subjects: 26
Study: 16881422

Group type: EXPERIMENTAL
Intervention: 400 micrograms of misoprostol applied three times in a 6 hour interval
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 600 micrograms of misoprostol applied three times in a 6 hour interval
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between the two dosages)
Number of subjects: 125
Study: 15658647

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) 1.2 g per day for 12 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional western medicine alone
Number of subjects: 105
Study: 11820258

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (l-AmB) prophylaxis, 1 mg kg(‐1) body weight, thrice-weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis (early intervention arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (l-AmB) prophylaxis
Number of subjects: 0
Study: 9668868

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (education + supervised exercise training)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Education-only program
Number of subjects: 59
Study: 8071246

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 2739756

Group type: EXPERIMENTAL
Intervention: 80 mg (R,S)-propranolol.HCl
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40 mg (S)-propranolol.HCl
Number of subjects: 24

Group type: COMPARATOR
Intervention: 40 mg (R)-propranolol.HCl
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 4885307

Group type: EXPERIMENTAL
Intervention: High-dosage anticoagulants (36 hours of heparin administration and phenindione at 72 mg/day)
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Low-dosage anticoagulants (1-mg tablets of phenindione)
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: High-dosage anticoagulants
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Low-dosage anticoagulants
Number of subjects: 1427
Study: 31926484

Group type: EXPERIMENTAL
Intervention: Caregiver provided 15-20 min daily of developmentally appropriate motor activities
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 99
Study: 29651600

Group type: EXPERIMENTAL
Intervention: Client self-report quality-of-care scale
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Clinician self-report quality-of-care scale
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Both client and clinician scales
Number of subjects: 658
Study: 28304290

Group type: EXPERIMENTAL
Intervention: Emotion recognition rehabilitation and cognitive stimulation therapy (CST)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cognitive stimulation therapy (CST)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Emotion recognition rehabilitation
Number of subjects: 36
Study: 27125141

Group type: EXPERIMENTAL
Intervention: UC-MSCs (2 million/kg body weight) administered through IV and IM injection
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no UC-MSCs)
Number of subjects: 11
Study: 23625592

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 113
Study: 21927687

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (intravenous saline)
Number of subjects: 130
Study: 19632048

Group type: EXPERIMENTAL
Intervention: ABT-594 150 microg BID
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: ABT-594 225 microg BID
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: ABT-594 300 microg BID
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 16763657

Group type: EXPERIMENTAL
Intervention: Epilenticular IOL implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: ACCC and PCCC with anterior vitrectomy
Number of subjects: 40
Study: 15205127

Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 25

Group type: COMPARATOR
Intervention: FSE-FLAIR and EPI-SE T2-weighted MR sequences
Number of subjects: 25

Group type: COMPARATOR
Intervention: EPI-GRE T2*-weighted MR sequence
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 25
Study: 11691758

Group type: EXPERIMENTAL
Intervention: School-based health promotion programme
Number of subjects: 634
Study: 9270637

Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy (cisplatin 70 mg/m2 and vindesine 3 mg/m2)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 205
Study: 8164503

Group type: EXPERIMENTAL
Intervention: Daily sublingual buprenorphine administration (4 mg/70 kg and 8 mg/70 kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Alternate-day buprenorphine administration (twice the daily maintenance dose every other day)
Number of subjects: 13
Study: 3291941

Group type: EXPERIMENTAL
Intervention: D-timolol (0.25%, 0.5%, 1.0%, and 2.0%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-timolol (0.25%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30704424

Group type: EXPERIMENTAL
Intervention: myCompass intervention (self-guided, fully automated)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 837
Study: 28271618

Group type: EXPERIMENTAL
Intervention: Plasma omega-3 docosapentaenoic acid (DPA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Plasma alpha linolenic acid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Plasma eicosapentaenoic acid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Plasma docosahexaenoic acid
Number of subjects: 120
Study: 26699167

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g in one dose)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 7 days)
Number of subjects: 567
Study: 23179647

Group type: EXPERIMENTAL
Intervention: Curette first followed by inflatable bone tamps (CF)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Inflatable bone tamps first followed by curettage and a second IBT inflation (IBTF)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IBTF group
Number of subjects: 112
Study: 21251084

Group type: COMPARATOR
Intervention: Plastic occlusion stress test followed by measurement of transepidermal water loss (TEWL) desorption curves
Number of subjects: 0
Study: 18464887

Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PALs)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Number of subjects: 92
Study: 22130404

Group type: EXPERIMENTAL
Intervention: Free Sprint Training (FST)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Resisted Sprint Training (RST)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Plyometrics Training (PT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: All groups (FST, RST, PT)
Number of subjects: 27
Study: 15913878

Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration
Number of subjects: 30

Group type: COMPARATOR
Intervention: No infiltration (Control)
Number of subjects: 30
Study: 14986682

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 252

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 252

Group type: COMPARATOR
Intervention: Memantine + Donepezil
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo + Donepezil
Number of subjects: 252
Study: 9934897

Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 2 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 43
Study: 2179282

Group type: EXPERIMENTAL
Intervention: CR/ZOK formulation of metoprolol (100 mg od, increased to 200 mg od for nonresponders)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional metoprolol tablets (50 mg bid, increased to 100 mg bid for nonresponders)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study: 6933163

Group type: EXPERIMENTAL
Intervention: 0.1% SnF2 mouthrinse (250 ppmF‐) used twice daily for 5 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo rinse used twice daily for 5 days
Number of subjects: 29
Study: 29719944

Group type: EXPERIMENTAL
Intervention: Lighter, smaller football (INT, N.=12 teams)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Traditional FIFA size 5 football (CON, N.=14 teams)
Number of subjects: 346
Study: 27517842

Group type: EXPERIMENTAL
Intervention: IV opioid initiated within 60 min
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Higher initial opioid dose (mg/kg/hr of morphine equivalents)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Higher initial opioid doses (6 mg vs -2.2 mg)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Oral opioids initiated within 24 hr
Number of subjects: 204
Study: 24457421

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n=10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sedentary attention control group (n=8)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 18
Study: 22484992

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) - with counselor training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Minimal Intervention (MI) - developing action plans for promotion and free access
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 44
Study: 20147878

Group type: EXPERIMENTAL
Intervention: Group-based multidisciplinary biopsychosocial rehabilitation program (12-week program, 73 hours of therapist exposure)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Intensive individual therapist-assisted back muscle strengthening exercises (12-week program, 24 hours of therapist exposure)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 286
Study: 18384675

Group type: EXPERIMENTAL
Intervention: EASYcare-based Dementia Training Program (DTP) consisting of two workshops, a coaching program, access to an internet forum, and a Computerized Clinical Decision Support System on dementia diagnostics.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (1/3 of the participants).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EASYcare-based Dementia Training Program (DTP)
Number of subjects: 100
Study: 16603964

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg) in normotensive controls
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg) in hypertensive patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg) in both groups
Number of subjects: 38

Group type: COMPARATOR
Intervention: L-NMMA effect on RCF
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cross-sectional area of CRA
Number of subjects: 38
Study: 14662591

Group type: EXPERIMENTAL
Intervention: Topical 1% rimexolone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Topical 0.1% fluorometholone
Number of subjects: 54
Study: 11712421

Group type: EXPERIMENTAL
Intervention: Streptokinase, heparin, and aspirin (Group B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Heparin and aspirin (Group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 29
Study: 9120105

Group type: EXPERIMENTAL
Intervention: Initial flow rate
Number of subjects: 11
Study: 1477610

Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study: 6486521

Group type: EXPERIMENTAL
Intervention: Short-acting quinidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Long-acting quinidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Quinidine therapy (both short-acting and long-acting)
Number of subjects: 21
Study: 31468412

Group type: EXPERIMENTAL
Intervention: Taurine supplement (TG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Taurine and lotus seeds supplement (TLG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 46
Study: 29360622

Group type: EXPERIMENTAL
Intervention: ELN-2017 risk stratification system
Number of subjects: 0

Group type: COMPARATOR
Intervention: ELN-2010 risk stratification system
Number of subjects: 0
Study: 26467048

Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplements
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference food (glucose beverage)
Number of subjects: 48
Study: 25062111

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urban US neonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: European neonates
Number of subjects: 0
Study: 22467902

Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by exemestane
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Combined analysis of patients reporting either menopausal symptoms or arthralgia/myalgia
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Control group (not reporting symptoms)
Number of subjects: 1502
Study: 20043248

Group type: EXPERIMENTAL
Intervention: Sound A
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sound B
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Washout
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sound A and Sound B
Number of subjects: 28
Study: 17828588

Group type: EXPERIMENTAL
Intervention: Objective housing stability
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Subjective housing stability
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Supportive housing
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Number of residences in the last 6 months
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Housing services needs
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Changes in housing status
Number of subjects: 493
Study: 16122590

Group type: EXPERIMENTAL
Intervention: 2-week postoperative follow-up appointment
Number of subjects: 48

Group type: COMPARATOR
Intervention: No follow-up
Number of subjects: 48
Study: 12090962

Group type: EXPERIMENTAL
Intervention: A-CASI (in-home self-administered audio computer assisted self interview)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: A-CASI and Telephone interview
Number of subjects: 223
Study: 10517211

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 7670449

Group type: EXPERIMENTAL
Intervention: Aspartate supplementation (ASP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 12
Study: 2175354

Group type: EXPERIMENTAL
Intervention: captopril at 75 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: atenolol at 100 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: canrenoate potassium at 200 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: combined group of atenolol and captopril responders (n = 22)
Number of subjects: 42
Study: 7030750

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg x 4 (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg x 4 (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg x 4 (Group 3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol (all groups)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol (Groups 2 and 3)
Number of subjects: 30
Study: 30991240

Group type: EXPERIMENTAL
Intervention: Comprehensive functional exercises including deep breathing and lower limb motions
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Functional exercise
Number of subjects: 132
Study: 30170597

Group type: EXPERIMENTAL
Intervention: Osurnia (terbinafine, florfenicol, betamethasone)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Osurnia
Number of subjects: 284

Group type: COMPARATOR
Intervention: Osurnia and Placebo
Number of subjects: 284
Study: 26577867

Group type: EXPERIMENTAL
Intervention: Video-based condition (VC)
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Text-based condition (TC)
Number of subjects: 2100
Study: 24255159

Group type: EXPERIMENTAL
Intervention: Small hood
Number of subjects: 16

Group type: COMPARATOR
Intervention: Large hood
Number of subjects: 16

Group type: COMPARATOR
Intervention: Small hood and Large hood
Number of subjects: 16
Study: 22068817

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen according to ATP‐CRA (Group B)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen (Group A)
Number of subjects: 63
Study: 20082342

Group type: EXPERIMENTAL
Intervention: RAP education program
Number of subjects: 287
Study: 17414675

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg a day
Number of subjects: 101

Group type: COMPARATOR
Intervention: Indapamide 2.5 mg a day
Number of subjects: 101
Study: 16343099

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day for 6 weeks
Number of subjects: 19
Study: 11882828

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 microg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tranexamic acid (10 mg/kg loading dose followed by 1 mg.kg(‐1).h(‐1) for 12 hours)
Number of subjects: 100
Study: 11835848

Group type: EXPERIMENTAL
Intervention: Yellow wavelength laser therapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Red wavelength laser therapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Green wavelength laser therapy
Number of subjects: 89
Study: 8949573

Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GHRH+GHRP-2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GHRH+GHRP-2 + TRH
Number of subjects: 40
Study: 2022012

Group type: EXPERIMENTAL
Intervention: Aspirin (162.5 mg) + Argatroban (1 micrograms/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Argatroban (1 micrograms/kg/min) alone
Number of subjects: 6
Study: 6177374

Group type: EXPERIMENTAL
Intervention: Purified human leucocyte interferon administered by repeated nasal sprays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 31064371

Group type: EXPERIMENTAL
Intervention: Job Management Program (JUMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 29305890

Group type: EXPERIMENTAL
Intervention: Cognitive training program consisting of six training sessions with cognitive tasks aimed at enhancing inhibition towards unhealthy food items and decreasing food approach and attentional biases
Number of subjects: 36

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 36
Study: 26880285

Group type: EXPERIMENTAL
Intervention: Appearance comparison instruction
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Peer norms instruction
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 246
Study: 24954556

Group type: EXPERIMENTAL
Intervention: Overshadowing by salient tasting beverages (OS+)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment (familiar beverage, water; OS-)
Number of subjects: 24
Study: 22446097

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study: 19096921

Group type: EXPERIMENTAL
Intervention: Risperidone plus structured parent training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone only
Number of subjects: 0
Study: 17585213

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224